We are live on ! Find out more
RPTX

Repare Therapeutics

Delisted

RPTX was delisted on the 27th of January, 2026.

50 hedge funds and large institutions have $29.1M invested in Repare Therapeutics in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $2K | Put options by funds: $1K

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

2.63% less ownership

Funds ownership: 72.05%69.42% (-2.6%)

7% less funds holding

Funds holding: 5450 (-4)

27% less capital invested

Capital invested by funds: $40.1M → $29.1M (-$11M)

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

38% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 16

Holders
50
Holders Change
-4
Holders Change %
-7.41%
% of All Funds
0.67%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
10
Reduced
16
Closed
13
Calls
$2K
Puts
$1K
Net Calls
+$1K
Net Calls Change
-$15K

RPTX Hedge Fund Activity: Q1 2025 in Review

50 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q1 2025, worth a combined $29.1M — down 27% from $40.1M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of RPTX and 9 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 10 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $1.13M. The largest seller was ARK Investment Management, cutting an estimated $1.06M.

  • 50 institutional investors held Repare Therapeutics (RPTX) as of Q1 2025, down from 54 in Q4 2024.
  • Funds reported $29.1M of Repare Therapeutics stock for Q1 2025, down 27% quarter-over-quarter.
  • 9 funds opened new Repare Therapeutics positions in Q1 2025 and 13 closed out, a net change of -4 holders.
  • The largest Repare Therapeutics buyer in Q1 2025 was Citadel Advisors, an estimated $1.13M added.
  • The largest Repare Therapeutics seller in Q1 2025 was ARK Investment Management, an estimated $1.06M sold.

Based on aggregated 13F filings for Q1 2025.